Brief: Ryvu Therapeutics Presents Development Plans For 2022-2024

Ryvu Therapeutics SA

19/08/2022 16:11

Aug 19 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * PRESENTS DEVELOPMENT PLANS FOR 2022-2024
    * UNDER GOALS FOR 2022-2024 TO ADVANCE CLINICAL DEVELOPMENT
OF
RVU120 AS  MONOTHERAPY
    * UNDER GOALS FOR 2022-2024 TO EXPAND THERAPEUTIC POTENTIAL
OF
RVU120 BY INITIATING PHASE I/II CLINICAL DEVELOPMENT
    * UNDER GOALS FOR 2022-2024 TO SUPPORT CLINICAL DEVELOPMENT
OF
PARTNERED CANDIDATE, SEL24 (MEN1703) BY MENARINI GROUP
    * UNDER GOALS FOR 2022-2024 TO ACHIEVE FINANCIAL MILESTONES
IN
EXISTING RESEARCH AND DEVELOPMENT COLLABORATIONS
    * UNDER GOALS FOR 2022-2024 TO ADVANCE SELECTED PROGRAMS BY
PARTNERING WITH COLLABORATORS WITH SYNERGISTIC COMPETENCIES  AND
RESOURCES
    * ANTICIPATES SPENDING APPROXIMATELY PLN 535 MILLION WITHIN
2ND
HALF OF 2022-2024

Source text for Eikon:  ID:nEM83QPKsa 
Further company coverage:  RVU.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))